Publication: A Survey for Human Tissue-Level Determinants of CAV1 Regulation and Function.
Loading...
Identifiers
Publication date
Advisors
Journal Title
Journal ISSN
Volume Title
Publishers
Multidisciplinary Digital Publishing Institute (MDPI)
Abstract
CAV1 is a protein-coding gene linked to several disorders, including cancer, lipodystrophy, and cardiovascular diseases. While its ability to respond to various mechanical and metabolic stimuli has been documented, a comprehensive understanding of its physiological regulation in humans is lacking. We leveraged the comprehensiveness of human post-mortem tissue data from the Genotype-Tissue Expression (GTEx) consortium, systematically exploring the sources of variability in CAV1 transcriptional levels using extensive bulk and single-nuclei RNA-seq datasets. This human-centric approach, avoiding inter-species comparisons, constitutes a unique resource to explore CAV1 regulation within the complexity of human tissues. Notably, cell type proportion was identified as a major determinant of CAV1 transcription levels across tissues. Donor physiological conditions, including disease states and end-of-life circumstances, also exhibited a tissue-specific influence. Among primary upstream regulators associated with CAV1, chromatin modifiers stood out, especially SMARCA2, which showed a positive correlation across tissues, and PRC2 complexes, which exhibited tissue-specific correlation. Upstream regulatory networks determining CAV1 levels are also enriched for annotations such as mechanobiology (e.g., TEAD4), immunity (e.g., RELA and STAT3), and metabolism (e.g., MYC and NRF1). A remarkable observation was a strong correlation between CAV1 and the relative infiltration of immune cells across tissues, supporting a potential role for CAV1 as a marker and driver of tissue immune infiltration.
Description
M.Á.d.P. is a recipient of grants from the Spanish Ministry of Science and Innovation (MCIN) (refs. SAF2017–83130-R cofunded by “ERDF A way of making Europe”, PID2020-118658RB-I00, PDC2021–121572-100 cofunded by “European Union NextGeneration EU/PRTR”), Asociación Española Contra el Cáncer foundation (AECC; PROYE20089DELP); La Marató TV3 foundation (201936–30-31), Fundación Obra social La Caixa (AtheroConvergence, HR20–00075; of which he is the coordinator) and Comunidad Autónoma de Madrid/FEDER (Tec4Bio consortium, ref. S2018/NMT¬4443). M.S.-Á. is a recipient of a Ramón y Cajal research contract from MCIN (RYC2020–029690-I) and research grants PID2021-128106NA-I00 and CNS2023-144831, all from Spanish MCIN. M.Á.d.P. received funding from the European Union’s Horizon 2020 research and innovation program under the Marie Skłodowska-Curie grant agreement 641639 in the context of the BIOPOL ITN consortia, of which V.J.-J. was an ESR. V.J.-J. was also supported by the La Caixa and Deutscher Akademischer Austauschdienst scholarship. M.A.S. is Robert W. Berliner Professor of Medicine and co-recipient of the AtheroConvergence grant from Fundación Obra social La Caixa (HR20–00075). The CNIC is
supported by the Instituto de Salud Carlos III (ISCIII), the Ministerio de Ciencia e Innovación (MCIN), and the Pro CNIC Foundation, and is a Severo Ochoa Center of Excellence (grant CEX2020-001041-S funded by MICIN/AEI/10.13039/501100011033). The Genotype-Tissue Expression (GTEx) Project was supported by the Common Fund of the Office of the Director of the National Institutes of Health, and by NCI, NHGRI, NHLBI, NIDA, NIMH, and NINDS.
MeSH Terms
DeCS Terms
Bibliographic citation
Int J Mol Sci. 2025 Apr 17;26(8):3789.





